Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer

Setsuko K. Chambers, Mary C. Clouser, Amanda F. Baker, Denise J. Roe, Haiyan Cui, Molly A. Brewer, Kenneth D. Hatch, Michael S. Gordon, Mike F. Janicek, Jeffrey D. Isaacs, Alan N. Gordon, Raymond B. Nagle, Heather M. Wright, Janice L. Cohen, David S. Alberts

Research output: Contribution to journalArticlepeer-review

49 Scopus citations

Fingerprint

Dive into the research topics of 'Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences